Olema Pharmaceuticals (OLMA) Net Income towards Common Stockholders (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$145.1 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 358.18% year-over-year to -$145.1 million in Q1 2026; TTM through Mar 2026 was -$279.5 million, a 31.89% decrease from a year earlier, with the FY2025 full-year figure at -$398.1 million, down 190.41% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$145.1 million, down from -$46.1 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for OLMA reached as high as -$25.8 million in Q3 2022 and fell as low as -$145.1 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$50.8 million across 5 years, with a median of -$42.5 million in 2025.
• Across the five-year window, Net Income towards Common Stockholders jumped 78.22% in 2022 and sank 358.18% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$26.6 million in 2022, then decreased by 2.1% to -$27.1 million in 2023, then declined by 24.52% to -$33.8 million in 2024, then plunged by 36.39% to -$46.1 million in 2025, then plunged by 214.93% to -$145.1 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$145.1 million in Q1 2026, -$46.1 million in Q4 2025, and -$42.5 million in Q3 2025.